JRCT ID: jRCT2080225048
Registered date:03/02/2020
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 14/01/2020 |
Target sample size | 52 |
Countries of recruitment | Japan,Asia except Japan,North America,South America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Venetoclax Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy confirmatory |
---|---|
Secondary Outcome | safety efficacy pharmacokinetics other |
Key inclusion & exclusion criteria
Age minimum | >= 12age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | AbbVie G.K. |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04161885,JapicCTI-205142 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-120-587-874 |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | |
Affiliation |